Eli Lilly is mentioned as a competitor that has gained significant ground in the obesity and diabetes medication market, impacting Novo Nordisk.
Source Post
🟢NOVO NORDISK: ¿TODAVÍA estamos a tiempo de INVERTIR?🤔 | 👉Análisis + VALORACIÓN 2026Q3
Sep 1, 2026
The creator provides an updated valuation and analysis of Novo Nordisk, discussing its past growth, the impact of competitors like Eli Lilly, and the potential for future recovery. The video aims to determine if it's still a good time to invest in the company, with the creator sharing their personal investment status and buying activity.
Linked Mentions
Tickers discussed in this post
Novo Nordisk, after a significant drop from its peak, is being re-evaluated for its investment potential, with the creator questioning if it's still a good time to buy.
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.